gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1202Research ArticleГЕПАТОЛОГИЯHEPATOLOGYОпухоль Клатскина (Обзор литературы)Klatskin tumor (Review of literature)МаевИ. В.MayevI. V.

Маев Игорь Вениаминович – доктор медицинских наук, профессор, член-корреспондент РАМН, директор Департамента медицинского образования и кадровой политики в здравоохранении Министерства здравоохранения РФ, заведующий кафедрой пропедевтики внутренних болезней и гастроэнтерологии

proped@mail.ruДичеваД. Т.DichevaD. T.

Дичева Диана Тодоровна – кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии 

di.di4eva@yandex.ruАндреевД. Н.AndreyevD. N.

Андреев Дмитрий Николаевич – аспирант кафедры пропедевтики внутренних болезней и гастроэнтерологии 

ПенкинаТ. В.PenkinaT. V.

Пенкина Татьяна Васильевна – кандидат медицинских наук, заслуженный врач РФ, полковник внутренней службы, начальник 4-го терапевтического отделения

ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РФРоссияState educational government-financed institution of higher professional education «Moscow State University of Medicine and Dentistry named after A.I. Evdokimov» Ministry of Healthcare of the Russian FederationRussian FederationФКУЗ «Главный клинический госпиталь МВД России»РоссияFederal healthcare government agency «Main clinical hospital Ministry of Internal Affairs of the Russian Federation»Russian Federation2013200720132333338Copyright © Маев И.В., Дичева Д.Т., Андреев Д.Н., Пенкина Т.В., 20132013Маев И.В., Дичева Д.Т., Андреев Д.Н., Пенкина Т.В.Mayev I.V., Dicheva D.T., Andreyev D.N., Penkina T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1202

Цель обзора. Статья посвящена обзору накопленных литературных данных о редкой форме холангиокарциномы, локализованной в области бифуркации печеночных протоков и названной в честь Джеральда Клатскина.Основные положения. Ведущим клиническим проявлением данного заболевания является обструктивная желтуха с отсутствием абдоминального болевого синдрома. Гистологическая картина представлена аденокарциномой ацинарного, тубулярного, трабекулярного, альвеолярного или папиллярного типа. Приведена классификация Bismuth– Corlette, позволяющая более точно дифференцировать локализацию поражения печеночных протоков;Заключение. Трудности распознавания и верификации опухоли Клатскина определяют широкое поле для дифференциальной диагностики. В силу нечастого распространения заболевание может представлять серьезную проблему в определении генеза холестатического синдрома.

The aim of review

The aim of review. Article reviews of cumulated literature data on the rare form of cholangiocarcinoma in bifurcation of hepatic ducts and named after Gerald Klatskin.

Key points

Key points. Obstructive jaundice at the absence of abdominal pain is leading clinical symptom of this disease. The histological pattern is represented by adenocarcinoma of acinar, tubular, trabecular, alveolar or papillary types. Bismuth-Corlette classification, that allows more precise differentiation of hepatic ducts lesion localization, is presented; diagnostic methods are discussed in details.

Conclusion

Conclusion. Difficulties of diagnosis and verification of Klatskin tumor determine a broad field for differential diagnostics. By virtue of low frequency disease represents a serious problem in assessment of cholestatic syndrome origin.

холангиокарциномаопухоль КлатскинажелтухахолестазcholangiocarcinomaKlatskin tumorjaundicecholestasisReferencesВишневский В.А., Тарасюк Т.И. Диагностика и хирургическое лечение рака проксимальных отделов внепеченочных желчных протоков (опухоль Клатскина)// Практическая онкология. – 2004. – Т. 5, № 2. – С. 126–134.Вишневский В.А., Тарасюк Т.И. Диагностика и хирургическое лечение рака проксимальных отделов внепеченочных желчных протоков (опухоль Клатскина)// Практическая онкология. – 2004. – Т. 5, № 2. – С. 126–134.Ультразвуковая диагностика в абдоминальной и сосудистой хирургии / Под. ред. Кунцевич Г.И. – Минск, 1999. – 252 с.Ультразвуковая диагностика в абдоминальной и сосудистой хирургии / Под. ред. Кунцевич Г.И. – Минск, 1999. – 252 с.Федоров В.Д., Вишневский В.А., Кубышкин В.А. и др. Хирургическое лечение рака общего печеночного протока // Кремлевская мед. – 2000. – № 2. – С. 13–16.Федоров В.Д., Вишневский В.А., Кубышкин В.А. и др. Хирургическое лечение рака общего печеночного протока // Кремлевская мед. – 2000. – № 2. – С. 13–16.Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma:Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma:–2009. World J Gastroenterol. 2009; 15 (34):4240–62.–2009. World J Gastroenterol. 2009; 15 (34):4240–62.Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007; 247:301–8.Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007; 247:301–8.Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma – the influence of sampling time and hepatolithiasis. Hepatogastroenterology. 2002; 49:616–20.Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma – the influence of sampling time and hepatolithiasis. Hepatogastroenterology. 2002; 49:616–20.Dawson JL, Heaton ND. Carcinoma of the biliary tree and gallbladder. Surgery Inter Edit. 2006; 17:84–8.Dawson JL, Heaton ND. Carcinoma of the biliary tree and gallbladder. Surgery Inter Edit. 2006; 17:84–8.De Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. NEJM. 1999; 341 (18):1368–78.De Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. NEJM. 1999; 341 (18):1368–78.Hann LE, Getrajdman GI, Brown KT, et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol. 1996; 167:1017–21.Hann LE, Getrajdman GI, Brown KT, et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol. 1996; 167:1017–21.Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg. 1999; 134:261–6.Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg. 1999; 134:261–6.Klatskin G. Adenocarcinoma of the hepatic ducts at its bifurcation within the porta hepatis. Am J Med, 1965; 38:241–56.Klatskin G. Adenocarcinoma of the hepatic ducts at its bifurcation within the porta hepatis. Am J Med, 1965; 38:241–56.Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010; 4:371–7.Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010; 4:371–7.Lee HY, Kim SH, Lee JM, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology. 2006; 239:113–21.Lee HY, Kim SH, Lee JM, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology. 2006; 239:113–21.Mihalache F, Tantau M, Diaconu B, et al. M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis 2010; 9:285–90.Mihalache F, Tantau M, Diaconu B, et al. M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis 2010; 9:285–90.NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V 1.2011. 1. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V 1.2011. 1. National Comprehensive Cancer Network.Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol. 2004; 18:147–54.Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol. 2004; 18:147–54.Ouchi K, Matsuno S, Sato T. Long – term survival in carcinoma of biliary tract. Arch Surg. 2007; 124:248–52.Ouchi K, Matsuno S, Sato T. Long – term survival in carcinoma of biliary tract. Arch Surg. 2007; 124:248–52.Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006; 3:33–42.Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006; 3:33–42.Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s Pharmacology. Elsevier Churchill Livingstone. 2007. – 792 p.Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s Pharmacology. Elsevier Churchill Livingstone. 2007. – 792 p.Romagnuolo J, Bardou M, Rahme E, et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med. 2003; 139:547–57.Romagnuolo J, Bardou M, Rahme E, et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med. 2003; 139:547–57.Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist. 2006; 11:913–22.Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist. 2006; 11:913–22.Somer L, Andrejić B, Milošević P. Origin and pathological characteristics of Klatskin tumor: a case report and literature review. Pol J Pathol. 2012; 63 (1):65–70.Somer L, Andrejić B, Milošević P. Origin and pathological characteristics of Klatskin tumor: a case report and literature review. Pol J Pathol. 2012; 63 (1):65–70.Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996; 223:384–94.Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996; 223:384–94.Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005; 16 (suppl 2):93–6.Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005; 16 (suppl 2):93–6.Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg. 2000; 87:306–13.Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg. 2000; 87:306–13.Tsuzuki T, Ogata Y, Lida S, et al. Carcinoma of the bifurcation of the hepatic ductus. Arch. Surg. 1987; 205 (2):111–8.Tsuzuki T, Ogata Y, Lida S, et al. Carcinoma of the bifurcation of the hepatic ductus. Arch. Surg. 1987; 205 (2):111–8.

The authors declare that there are no conflicts of interest present.